Hyloris Developmentsen Sa (HYL) - Total Liabilities
Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has total liabilities worth €8.16 Million EUR (≈ $9.54 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hyloris Developmentsen Sa asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Hyloris Developmentsen Sa - Total Liabilities Trend (2016–2024)
This chart illustrates how Hyloris Developmentsen Sa's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see HYL asset base.
Hyloris Developmentsen Sa Competitors by Total Liabilities
The table below lists competitors of Hyloris Developmentsen Sa ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S&P Syndicate Public Company Limited
BK:SNP
|
Thailand | ฿1.52 Billion |
|
Ally Leasehold Real Estate Investment Trust
BK:ALLY
|
Thailand | ฿5.02 Billion |
|
Stealth Group Holdings Ltd
AU:SGI
|
Australia | AU$91.05 Million |
|
Flügger group A/S
CO:FLUG-B
|
Denmark | Dkr969.00 Million |
|
UPDATER SERVICES LIMITED
NSE:UDS
|
India | Rs5.84 Billion |
|
Bank Jabar
JK:BJBR
|
Indonesia | Rp195.94 Trillion |
|
Cypark Resources Berhad
KLSE:5184
|
Malaysia | RM2.28 Billion |
|
Cape Industries Ltd
KQ:064820
|
Korea | ₩4.26 Trillion |
Liability Composition Analysis (2016–2024)
This chart breaks down Hyloris Developmentsen Sa's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HYL equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hyloris Developmentsen Sa's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hyloris Developmentsen Sa (2016–2024)
The table below shows the annual total liabilities of Hyloris Developmentsen Sa from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.19 Million ≈ $10.75 Million |
+6.73% |
| 2023-12-31 | €8.61 Million ≈ $10.07 Million |
+26.29% |
| 2022-12-31 | €6.82 Million ≈ $7.97 Million |
-55.69% |
| 2021-12-31 | €15.39 Million ≈ $17.99 Million |
+52.01% |
| 2020-12-31 | €10.12 Million ≈ $11.83 Million |
-37.40% |
| 2019-12-31 | €16.17 Million ≈ $18.91 Million |
+30.31% |
| 2018-12-31 | €12.41 Million ≈ $14.51 Million |
+43.45% |
| 2017-12-31 | €8.65 Million ≈ $10.11 Million |
+144.86% |
| 2016-12-31 | €3.53 Million ≈ $4.13 Million |
-- |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more